New developments in nuclear oncology, based on monoclonal antibodies and position emission tomography measurement of glucose metabolism promise to broaden the range of applications of nuclear medicine methods in the clinical management of patients with tumor. Perhaps of greatest importance, is the prospect of both diagnosing and treating common solid tumors, with the same radiolabeled (monoclonal antibody) pharmaceutical preparation.
